Czechoslovak Group Faces a Crisis of Confidence as May 20 Earnings Report Nears

The numbers tell two starkly different stories for Czechoslovak Group. On one side, revenue surged nearly 72% to €6.7 billion in 2025, the order book swelled to €42 billion, and management is guiding for sales of €7.4 billion to €7.6 billion this year with an EBIT margin of 24% to 25%. On the other, the stock has been cut in half since its January debut, trading at roughly €16 — a 53% collapse from the 52-week high of €33.81 and a 36% rout over the past 30 days alone.

That disconnect between operational performance and market valuation has become the defining feature of CSG's brief life as a public company. And with nine analysts all rating the stock a buy and setting an average price target of €35.40 — more than double the current level — the gap between Wall Street's optimism and the market's pessimism is screaming for resolution.

The first opportunity comes on May 20, when CSG delivers its inaugural quarterly earnings report since the IPO. That filing will also reveal the one-time costs tied to going public, giving investors their first concrete look at whether the company's margins can withstand the financial hangover of its stock market debut.

The SAFE Deadline That Nobody Is Talking About

While the short-seller drama has dominated headlines, a separate overhang looms in the form of the EU's SAFE financing program. The Slovak ammunition framework agreement — carrying a maximum volume of €58 billion — qualifies for SAFE funding at an interest rate of just 1%, provided at least two EU member states participate. That exemption expires at the end of May 2026.

Should investors sell immediately? Or is it worth buying CSG?

So far, no partner has committed. Romania's defense ministry denied ministerial-level talks. Croatia is studying participation but hasn't decided. Poland and Greece have offered only vague responses. CSG has stressed that the framework is a master agreement without firm orders and is not dependent on any single financing mechanism. From that Slovak framework, the company had booked roughly €1 billion in its pipeline at the time of its annual results.

The Short-Seller Attack and the Production Reality

The immediate trigger for the selloff was a report from Hunterbrook Media, whose affiliated investment vehicle Hunterbrook Capital holds a short position in CSG shares. The report questioned whether CSG is truly a munitions manufacturer at the scale its investor materials suggest, arguing that a significant portion of its business involves buying, refurbishing, and reselling existing ammunition rather than producing new rounds.

CSG fired back, calling the characterization inaccurate and the conclusions misleading. The company laid out concrete production numbers: its own manufacturing capacity stood at roughly 630,000 rounds in 2025, excluding reactivated facilities and external partnerships. For 2026, it plans roughly 20% growth, with a new production line in Slovakia adding 70,000 rounds of capacity. The medium-term target is 1.1 million rounds annually across sites in Slovakia, Greece, Serbia, Spain, and India.

A Shareholder Dispute Adds to the Noise

Czech media have also reported a dispute with minority shareholder Petr Kratochvíl, who allegedly exercised a put option just before the IPO and demanded roughly €1.4 billion for his stake in CSG Land Systems. CSG countered that a previously outstanding claim of €275 million — stemming from the pre-IPO sale of its Mobility, Perazzi, and Healthcare divisions — was fully settled in the first quarter of 2026, exactly as communicated at the time of the listing.

Strategic Moves and a Pending Austrian Deal

Away from the governance battles, CSG continues to execute. In late April, it announced a new contract from Western Europe worth nearly €250 million for 155-millimeter artillery ammunition. Its subsidiary Excalibur International secured defense orders in Southeast Asia valued at roughly €2.5 billion. And the planned acquisition of a 49% stake in Hirtenberger Defence Systems — CSG's first move into Austria — is awaiting regulatory clearance.

CSG at a turning point? This analysis reveals what investors need to know now.

The May 20 Inflection Point

The quarterly report on May 20 is the first real test of whether CSG can bridge the chasm between its operational strength and its battered stock price. If first-quarter numbers confirm the guidance, the pressure on short sellers could intensify. If they disappoint, management's narrative loses further credibility.

Either way, the gap between nine buy ratings and a stock trading at half the consensus target price cannot persist indefinitely. The next few weeks will determine which side of that divide is right.

Ad

CSG Stock: New Analysis - 9 May

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...

en | NL0015073TS8 | CZECHOSLOVAK | boerse | 69295717 |